These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9725545)

  • 1. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.
    Vachharajani NN; Shyu WC; Chando TJ; Everett DW; Greene DS; Barbhaiya RH
    J Clin Pharmacol; 1998 Aug; 38(8):702-7. PubMed ID: 9725545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.
    Davi H; Tronquet C; Miscoria G; Perrier L; DuPont P; Caix J; Simiand J; Berger Y
    Drug Metab Dispos; 2000 Jan; 28(1):79-88. PubMed ID: 10611144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
    Kostis JB; Vachharajani NN; Hadjilambris OW; Kollia GD; Palmisano M; Marino MR
    J Clin Pharmacol; 2001 Sep; 41(9):935-42. PubMed ID: 11549097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis.
    Marino MR; Langenbacher KM; Raymond RH; Ford NF; Lasseter KC
    J Clin Pharmacol; 1998 Apr; 38(4):347-56. PubMed ID: 9590462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers.
    Gu S; Chen H; Qiu Y; Shi S; Zeng F
    J Huazhong Univ Sci Technolog Med Sci; 2002; 22(1):14-6. PubMed ID: 12658772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects.
    Ghim JL; Paik SH; Hasanuzzaman M; Chi YH; Choi HK; Kim DH; Shin JG
    J Clin Pharmacol; 2016 May; 56(5):576-80. PubMed ID: 26272450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of age and gender on the pharmacokinetics of irbesartan.
    Vachharajani NN; Shyu WC; Smith RA; Greene DS
    Br J Clin Pharmacol; 1998 Dec; 46(6):611-3. PubMed ID: 9862252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of irbesartan in man.
    Chando TJ; Everett DW; Kahle AD; Starrett AM; Vachharajani N; Shyu WC; Kripalani KJ; Barbhaiya RH
    Drug Metab Dispos; 1998 May; 26(5):408-17. PubMed ID: 9571222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.
    Lo MW; Goldberg MR; McCrea JB; Lu H; Furtek CI; Bjornsson TD
    Clin Pharmacol Ther; 1995 Dec; 58(6):641-9. PubMed ID: 8529329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
    Flesch G; Müller P; Lloyd P
    Eur J Clin Pharmacol; 1997; 52(2):115-20. PubMed ID: 9174680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
    Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers.
    Vachharajani NN; Shyu WC; Mantha S; Park JS; Greene DS; Barbhaiya RH
    J Clin Pharmacol; 1998 May; 38(5):433-6. PubMed ID: 9602956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug clinics. Drug of the month. Irbesartan (Aprovel)].
    Kulbertus H
    Rev Med Liege; 1999 Feb; 54(2):125-7. PubMed ID: 10221067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
    Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
    Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
    Ruilope L
    J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.
    Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W
    Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
    Schmitt F; Martinez F; Brillet G; Nguyen-Khoa T; Brouard R; Sissmann J; Lacour B; Grunfeld JP
    J Cardiovasc Pharmacol; 1998 Feb; 31(2):314-21. PubMed ID: 9475275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
    Belz GG; Butzer R; Kober S; Mang C; Mutschler E
    Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
    Brunner HR
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):311S-317S. PubMed ID: 9438775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.